Post-operative nausea and vomiting are common complications after surgery. The researchers from Duke University Medical Center commented on rolapitant’s rapid absorption, remarkably long half-life and low potential for drug-drug interactions.
The researchers assigned groups to rolapitant in 5-mg, 20-mg, 70-mg and 200-mg doses, as well as IV ondansetron 4 mg and placebo. The researchers found that groups assigned to rolapitant 20-mg, 70-mg and 200-mg had a higher incidence of no vomiting in comparison with placebo at 24 hours after surgery.
No differences in side effect profile were observed between rolapitant and placebo.
Read the abstract on rolapitant in Anesthesia & Analgesia.
Read more on anesthesia:
–Sen. Blumenthal Requests GAO Investigation of Drug Shortages
–Airway Scope Intubation Successful in Laterally Positioned Patients
–FDA Cannot Draw Definitive Conclusion on Anesthesia in Young Children
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
